NewMoneyMoves
PerspectivesResearchTerminalsWeekend RWABoard
HomeEarningsRegeneron Pharmaceuticals FY2023 Q4
Released
FY2023 Q4
Earnings Review
REGN
BEAT

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals · Biotech/Pharma

Fri, February 2, 2024·Before Market Open
BiotechREGNEarnings

01Wall Street Consensus

EPS$10.89
Revenue$3.3B

02Earnings Results

EPS$11.29+3.7%
Revenue$3.4B+3.0%

Key Checkpoints

    Upside Catalysts

      Risk Factors

        Detail

        EEPS History (Last 12 Quarters)

        Actual EPS vs Consensus — Green Beat · Red Miss

        Beat11
        Miss1
        Beat rate92%
        Detail

        SEPS 서프라이즈 히스토리

        Beat11Miss1Beat률 92%

        분기별 EPS 컨센서스 대비 서프라이즈(%) — 막대: EPS, 점선: 매출

        컨센서스 대비 실제 EPS/매출 서프라이즈 (%)

        Comments

        Earnings
        Earnings Info
        SymbolREGN
        QuarterFY2023 Q4
        Report Date2024-02-02
        Report TimeBMO
        SectorBiotech/Pharma
        StatusReleased
        Wall Street Consensus
        EPS$10.89
        Revenue$3.3B
        Results
        Actual EPS$11.29
        Actual Revenue$3.4B
        NewMoneyMoves

        Global Investment through Themes

        Content

        ThemesIdeasReportsEarnings

        Explore

        GuideETFsPerspectivesTelegramNVIDIA PortfolioWeekly ReviewCredit & Leverage

        Community

        Daily News

        Legal

        Privacy PolicyTerms of ServiceDisclaimer

        © 2026 NewMoneyMoves. All rights reserved.